全反式维甲酸/三氧化二砷治疗小儿急性早幼粒细胞白血病中严重分化综合征的挑战性管理 - Suppr

Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO.

作者信息

Molinaro Alessandro, Zanta Daniela, Moleti Maria Luisa, Giona Fiorina, Conter Valentino, Rizzari Carmelo, Biondi Andrea, Testi Anna Maria

机构信息

Clinica Pediatrica, Università degli Studi di Milano Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma, Ospedale San Gerardo, Monza, Italy.

Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

出版信息

Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022027. doi: 10.4084/MJHID.2022.027. eCollection 2022.

DOI:10.4084/MJHID.2022.027

PMID:35444767

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8992615/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a93/8992615/1265dbefdf21/mjhid-14-1-e2022027f1.jpg

相似文献

Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO.

Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022027. doi: 10.4084/MJHID.2022.027. eCollection 2022.

Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.

Leuk Res. 2014 Aug;38(8):977-82. doi: 10.1016/j.leukres.2014.05.019. Epub 2014 Jun 4.

Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.

Leuk Res. 2018 Mar;66:85-88. doi: 10.1016/j.leukres.2018.01.019. Epub 2018 Feb 3.

Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.

Oncol Rep. 2012 Nov;28(5):1875-82. doi: 10.3892/or.2012.2006. Epub 2012 Aug 31.

The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells.

Front Oncol. 2021 Sep 28;11:686445. doi: 10.3389/fonc.2021.686445. eCollection 2021.

Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.

Cancer Res Treat. 2013 Jun;45(2):126-33. doi: 10.4143/crt.2013.45.2.126. Epub 2013 Jun 30.

[Therapies for newly diagnosed acute promyelocytic leukemia].

Rinsho Ketsueki. 2020;61(9):1166-1173. doi: 10.11406/rinketsu.61.1166.

All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.

Cell Death Dis. 2017 May 11;8(5):e2782. doi: 10.1038/cddis.2017.197.

[Acute promyelocytic leukemia: state-of-the-art management].

Rinsho Ketsueki. 2018;59(6):725-734. doi: 10.11406/rinketsu.59.725.

Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).

Pediatr Blood Cancer. 2019 Mar;66(3):e27542. doi: 10.1002/pbc.27542. Epub 2018 Nov 4.

引用本文的文献

Acute promyelocytic leukemia in children cancer hospital Egypt.

Discov Oncol. 2024 Jun 11;15(1):223. doi: 10.1007/s12672-024-01037-6.

Roles of PADI4 in the expression of cytokines involved in inflammation and adhesion in differentiated NB4 cells treated with ATRA.

Exp Ther Med. 2023 Jan 31;25(3):118. doi: 10.3892/etm.2023.11817. eCollection 2023 Mar.

本文引用的文献

Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.

Br J Haematol. 2020 Jan;188(1):170-173. doi: 10.1111/bjh.16364. Epub 2019 Dec 6.

Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.

Br J Haematol. 2019 Apr;185(2):360-363. doi: 10.1111/bjh.15507. Epub 2018 Jul 20.

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

Blood. 2018 Jul 26;132(4):405-412. doi: 10.1182/blood-2018-03-836528. Epub 2018 May 22.

Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab.

Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.

Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults.

Mediterr J Hematol Infect Dis. 2014 Apr 15;6(1):e2014032. doi: 10.4084/MJHID.2014.032. eCollection 2014.

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.

Blood. 2014 May 1;123(18):2777-82. doi: 10.1182/blood-2013-10-512640. Epub 2014 Mar 13.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.

The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011059. doi: 10.4084/MJHID.2011.059. Epub 2011 Dec 4.

Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011048. doi: 10.4084/MJHID.2011.048. Epub 2011 Oct 24.

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols.

Blood. 2012 Jan 5;119(1):49-54. doi: 10.1182/blood-2011-07-369595. Epub 2011 Nov 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献